8-K filed October 30, 2024, 7:59 PM ET ticker CNMD CIK 0000816956

earnings confidence high sentiment neutral materiality 0.85

CONMED Q3 2024: adj. EPS $1.05 beats; revenue guidance trimmed; CEO transition to Beyer Jan 2025

CONMED Corp

2024-Q3 EPS reported $3.17 revenue$961,071,000

Sales $316.7M (+4.0% YoY); GAAP EPS $1.57 (vs $0.50); adjusted EPS $1.05 (+16.7%).
Full-year revenue guidance lowered to $1.300–1.305B from $1.305–1.315B; adj. EPS raised to $4.00–4.05 from $3.95–4.02.
COO Pat Beyer appointed President and CEO effective Jan 1, 2025; Curt Hartman will retire and serve as Special Advisor through March 2027.
Hartman to receive consulting fee of $1.936M plus 2x avg bonus; equity vesting continues through separation date.
Domestic sales +7.4% YoY; international -0.4%; single-use products +6.9%, capital -10.6%.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Curt R. Hartman

Chair of the Board

CNMD · CONMED Corp

Effective: 2024-10-31
Filed: October 30, 2024, 7:59 PM ET

effective as of October 31, 2024, Curt R. Hartman’s service as Chair of the Board will cease

Role change

Curt R. Hartman

Special Advisor

CNMD · CONMED Corp

Effective: 2025-03-03
Filed: October 30, 2024, 7:59 PM ET

Commencing on March 3, 2025 (the 'Transition Date'), Mr. Hartman will serve as a Special Advisor

Departed

Curt R. Hartman

Special Advisor

CNMD · CONMED Corp

Effective: 2027-03-03
Filed: October 30, 2024, 7:59 PM ET

As of the Separation Date, Mr. Hartman’s service relationship with the Company will cease.

Role change

Curt R. Hartman

non-executive officer

CNMD · CONMED Corp

Effective: 2025-01-01
Successor: Pat Beyer
Filed: October 30, 2024, 7:59 PM ET

Effective as of January 1, 2025, Mr. Hartman will transition into a non-executive officer role

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Curt R. Hartman changed role as Chair of the Board at CONMED Corp.

Action: cease
Role: Chair of the Board

Exact text from the filing

effective as of October 31, 2024, Curt R. Hartman’s service as Chair of the Board will cease

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.9

Curt R. Hartman was appointed as Special Advisor at CONMED Corp.

Action: appointed
Role: Special Advisor

Exact text from the filing

Commencing on March 3, 2025 (the 'Transition Date'), Mr. Hartman will serve as a Special Advisor

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Curt R. Hartman departed as Special Advisor at CONMED Corp.

Action: will cease
Role: Special Advisor

Exact text from the filing

As of the Separation Date, Mr. Hartman’s service relationship with the Company will cease.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Curt R. Hartman changed role as non-executive officer at CONMED Corp.

Action: transitioned
Role: non-executive officer

Exact text from the filing

Effective as of January 1, 2025, Mr. Hartman will transition into a non-executive officer role

View on SEC.gov

CONMED Corp filing history →

Source: SEC EDGAR

accession 0001193125-24-247545

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.